Navigation Links
Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc.
Date:5/16/2010

TOKYO and MELVILLE, N.Y. May 16 /PRNewswire-FirstCall/ -- Astellas Pharma Inc. (TSE: 4503), a global pharmaceutical company, and OSI Pharmaceuticals, Inc. (Nasdaq: OSIP), a biotechnology company primarily focused on the discovery, development and commercialization of molecular targeted therapies addressing medical needs in oncology, diabetes and obesity, today announced that they have entered into a definitive merger agreement under which Astellas will acquire OSI.

Under the terms of the merger agreement, Astellas will increase its offer price to $57.50 per share, which represents a premium of 55% to the closing price for OSI's shares of $37.02 on February 26, 2010, the last trading day before the announcement by Astellas of its tender offer. The boards of directors of both companies have unanimously approved the combination. The all-cash transaction is valued at $4.0 billion on a fully diluted basis.

The combined company creates a world-class oncology platform supporting Astellas' stated growth strategy of becoming a Global Category Leader in Oncology, a high-priority therapeutic area for Astellas. OSI commercializes Tarceva® (erlotinib), a leading cancer medication. OSI's total annual revenues for 2009, as reported in its Form 10-K for the year ended December 31, 2009, were $428 million and operating income was $153 million.

Masafumi Nogimori, President and Chief Executive Officer of Astellas, said, "The merger with OSI prov
'/>"/>

SOURCE Astellas Pharma US, Inc.; OSI Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC
2. Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program
3. Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case
4. CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM) (regadenoson) Injection
5. Astellas Launches Lexiscan(TM) (Regadenoson) Injection for Use as a Pharmacologic Stress Agent in Radionuclide Myocardial Perfusion Imaging (MPI)
6. FDA Approves Astellas Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
7. CV Therapeutics Statement on Unsolicited Proposal From Astellas
8. CV Therapeutics Board of Directors Rejects Astellas Unsolicited Proposal
9. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
10. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
11. Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015  Array BioPharma Inc. (NASDAQ: ARRY ) ... with Novartis Pharma AG to acquire worldwide rights to ... development.  This agreement is conditional on the closing of transactions ... 2014, which are expected to close in the first ...
(Date:1/22/2015)... COLUMBIA, Md. (PRWEB) January 22, 2015 ... of its new UV-1280 multipurpose UV-visible spectrophotometer. Offering ... compact, high-quality instrument is ideal for applications in ... and life science. , The user-friendly UV-1280 enables ...
(Date:1/22/2015)... , Jan. 22, 2015  Transwestern | RBJ today announces ... of office space for Shire a leading biopharmaceutical company, at ... Transwestern | RBJ,s Robert Richards , president, and ... lease for the entire five-floor building at 95 Hayden Ave. ...
(Date:1/22/2015)... January 22, 2015 Protocol Networks brings ... growing team of brand-neutral, independent consultants, Protocol Networks has ... explained that over the years, his company has attracted ... Town of Plainfield, as well as others. With the ...
Breaking Biology Technology:Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 2Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 3Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 4Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 5Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 6Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 7Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2
... in Upfront Fees and Milestones -, DALLAS, ... ACCP) and Milestone Biosciences, LLC ("Milestone"),today announced the ... will market Access, proprietary product MuGard(TM) in the ... started by former,executives and sales representatives of companies ...
... Knowledge Databases ... Nuclear Receptors and Proteases, PARIS, August 18 ... accelerate life sciences discovery,announced today the release of three ... databases for the important,drug targets Nuclear Receptor and Protease, ...
... in 2008 on target; Potential label ... expansion could further drive sales, SEATTLE, ... reported financial results for the quarter,ended June 30, 2008. Total ... the second quarter of 2007 due primarily to sales,of Zevalin(R) ...
Cached Biology Technology:Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America 2Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America 3Aureus Pharma Releases New Unified Knowledge Database 2Cell Therapeutics, Inc.'s Second Quarter 2008 Financial Results 2Cell Therapeutics, Inc.'s Second Quarter 2008 Financial Results 3Cell Therapeutics, Inc.'s Second Quarter 2008 Financial Results 4Cell Therapeutics, Inc.'s Second Quarter 2008 Financial Results 5Cell Therapeutics, Inc.'s Second Quarter 2008 Financial Results 6Cell Therapeutics, Inc.'s Second Quarter 2008 Financial Results 7
(Date:1/22/2015)... 2015 , Europe,s ... The European Patent Office to present a video retrospective of the ... be featured: Christofer Toumazou and Sophie Wilson   ... winners of the Award   Starting on 22 January ...
(Date:12/24/2014)... in December 2014, the 1U™ app has helped ... remember their usernames and passwords through replacing the antiquated system ... people who have struggled to remember usernames and passwords, ... on redefining identity, announced today that it is offering the ...
(Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) has ... Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report" ... http://photos.prnewswire.com/prnh/20130307/600769 Following the acquisition of ... feature with the iPhone 5S. It is currently the ...
Breaking Biology News(10 mins):Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 31U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2
... has demonstrated that ancient DNA can be used to ... have broad reaching implications for understanding recent changes to ... been lost as a result of our current abundant ... Lewis Jr., professor of anthropology in the OU College ...
... Sons, Inc., The Physiological Society (TPS), and The ... to publish the new open access peer-reviewed journal, ... next year. Physiological Reports will ... translational and clinical physiology and allied disciplines for ...
... to be unique in toothed whales like dolphins has ... of Strathclyde. The research is challenging ideas about ... katydids hear, revealing the unexpected similarity to toothed whale ... Sciences at The University of Auckland, with colleagues from ...
Cached Biology News:OU study suggests the bacterial ecology that lives on humans has changed in the last 100 years 2Physiological societies partner with Wiley on new open access journal 2Dolphin hearing system component found in insects 2
Four siRNAs targeting your gene of interest, providing gene silencing with 100% satisfaction guaranteed High knockdown potency , High specificity for minimal off-target effects , Flexible siR...
... PHD2000 syringe pump series combines Harvard Apparatuss best ... and a wide range of configuration options. A ... dimensions of syringes from all the major manufacturers. ... all the pertinent information from across the lab. ...
... are used for heterologous protein expression in the ... S2 cell line was derived from a primary ... Drosophila melanogaster embryos (1). This versatile ... CO2 and is easily adapted to suspension culture. ...
... Harvard Apparatuss best pump mechanism, a well thought ... configuration options. A lookup table in the pumps ... the major manufacturers. A bright, two line display ... across the lab. All models have RS-232 and ...
Biology Products: